DJIA 17,598.20 -91.66 -0.52%
NASDAQ 5,115.38 -12.90 -0.25%
S&P 500 2,098.04 -5.80 -0.28%
market minute promo

554.27 0.61 (0.11%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

REGN $554.27 0.11%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $558.47
Previous Close $553.66
Daily Range $546.00 - $561.31
52-Week Range $314.00 - $569.92
Market Cap $57.2B
P/E Ratio 177.46
Dividend (Yield) $0.00 (0.0%)
Volume 700,275
Average Daily Volume 609,756
Current FY EPS $8.31

Sector

Healthcare

Industry

Drug Makers

Regeneron Pharmaceuticals, Inc. (REGN) Description

The Company is a biopharmaceutical company that discovers, develops, and intends to commercialize pharmaceutical products for the treatment of serious medical conditions. Website: http://www.regeneron.com/

News & Commentary Rss Feed

Regeneron Pharmaceuticals and Sanofi Grab a Blockbuster FDA Approval

The FDA has given the nod to the sale of Praluent, the first of a new class of cholesterol lowering medications, and a blockbuster opportunity for the company's.

5 Biotechs With Catalysts Coming This Week

Pre-Market Earnings Report for August 4, 2015 : CVS, REGN, AET, EMR, ADM, SRE, ZTS, HCN, K, CHTR, I

Pre-Market Earnings Report for August 4, 2015 : CVS, REGN, AET, EMR, ADM, SRE, ZTS, HCN, K, CHTR, INCY, HCP

MYL, REGN And AMGN, 3 Drugs Stocks Pushing The Industry Lower

Game Plan For The Week - Cramer's Mad Money (7/31/15)

Will Regeneron (REGN) Earnings Surprise on Eylea Sales? - Analyst Blog

Sanofi Tops Q2 Earnings, Revenues Grow Y/Y, Maintains View - Analyst Blog

The Zacks Analyst Blog Highlights: Biogen, AbbVie, Regeneron, Amgen and XOMA - Press Releases

Regeneron's Mega-Blockbuster Potential With Praluent: CVS Health Sees It, So Why Don't More Analysts

Regeneron's Mega-Blockbuster Potential With Praluent: CVS Health Sees It, So Why Don't More Analysts?

Sanofi & Regeneron Enter Immuno-Oncology Collaboration - Analyst Blog

Biotech Stock Roundup: Biogen Down on Tecfidera Issues, Regeneron's Praluent Gets FDA Nod - Analyst

Biotech Stock Roundup: Biogen Down on Tecfidera Issues, Regeneron's Praluent Gets FDA Nod - Analyst Blog

See More REGN News...

REGN's Top Competitors

REGN $554.27 (0.11%)
Current stock: REGN
AMGN $175.59 (-0.57%)
Current stock: AMGN
GILD $119.60 (1.48%)
Current stock: GILD
BIIB $324.38 (1.76%)
Current stock: BIIB